Systemic Lupus Erythematosus with Autoimmune Myelofibrosis, Immune Thrombocytopenic Purpura, and Widespread Lytic Bone Lesions Successfully Treated with Rituximab and Romiplostim: a Case-Based Review

2021 ◽  
Vol 3 (2) ◽  
pp. 584-589
Author(s):  
Tejasvi K. Dasari ◽  
Jake Jacob ◽  
Annie Dai ◽  
Albert Jang ◽  
Lee Bach Lu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Immune Thrombocytopenic Purpura ◽  
Bone Lesions ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura ◽  
Lytic Bone Lesions ◽  
Case Based

scholarly journals Systemic Lupus Erythematosus, Immune Thrombocytopenic Purpura, and Autoimmune Hemolytic Anemia

2009 ◽  
Vol 2 (2) ◽  
pp. 43-47
Author(s):  
Natacha Esber ◽  
Katherine Howle ◽  
Sylvia Orozco-Do ◽  
Phu Truong ◽  
Michael E Grant ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Hemolytic Anemia ◽  
Lupus Erythematosus ◽  
Immune Thrombocytopenic Purpura ◽  
Autoimmune Hemolytic Anemia ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura

scholarly journals An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review

2021 ◽  
pp. 1-5
Author(s):  
Maya Kornowski Cohen ◽  
Liron Sheena ◽  
Yair Shafir ◽  
Vered Yahalom ◽  
Anat Gafter-Gvili ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Lupus Erythematosus ◽  
Response To Therapy ◽  
Intravascular Hemolysis ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura ◽  
History Of ◽  
Triggering Factor

SARS-CoV-2 has been reported as a possible triggering factor for the development of several autoimmune diseases and inflammatory dysregulation. Here, we present a case report of a woman with a history of systemic lupus erythematosus and antiphospholipid syndrome, presenting with concurrent COVID-19 infection and immune thrombotic thrombocytopenic purpura (TTP). The patient was treated with plasma exchange, steroids, and caplacizumab with initial good response to therapy. The course of both TTP and COVID-19 disease was mild. However, after ADAMTS-13 activity was normalized, the patient experienced an early unexpected TTP relapse manifested by intravascular hemolysis with stable platelet counts requiring further treatment. Only 3 cases of COVID-19 associated TTP were reported in the literature thus far. We summarize the literature and suggest that COVID-19 could act as a trigger for TTP, with good outcomes if recognized and treated early.

scholarly journals Thrombotic thrombocytopenic purpura and systemic lupus erythematosus.

1986 ◽  
Vol 45 (4) ◽  
pp. 319-322 ◽  
Author(s):  
D A Fox ◽  
J D Faix ◽  
J Coblyn ◽  
P Fraser ◽  
B Smith ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura

scholarly journals Thrombotic Thrombocytopenic Purpura in a Patient with Systemic Lupus Erythematosus

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Guavita-Navarro Diana ◽  
Cajamarca-Baron Jairo ◽  
Buitrago-Bohorquez Jhon ◽  
Gallego-Cardona Laura ◽  
Guevara Diana ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura
Sign in / Sign up

Export Citation Format

Share Document